Introduction
Vaccinia virus has been widely used as a eukaryotic expression vector (for review see Mackett & Smith, 1986) . Because it has also been used as a successful vaccine against smallpox there has been great interest in the possibility of using recombinant vaccinia viruses as live vaccines in humans and in animals. The expression of a wide range of pathogen genes has led to the development of many prototype vaccines and their testing in model systems. However, the fact that serious side effects were occasionally associated with the use of vaccinia as a vaccine (Lane et al., 1969) has meant that there is a reluctance to use recombinant vaccinia viruses as vaccines for human and veterinary diseases. In the veterinary field interest has more recently focused on the development of species-specific poxviruses as potential vaccine vectors, for example avipoxviruses in poultry (Binns et al., 1986; Boyle & Coupar, 1988) and capripoxviruses in sheep and goats (Gershon & Black, 1989) .
Fowlpox virus (FPV), the prototypic avipoxvirus, has a host range limited to avian species (Tripathy & Cunningham, 1984) and would therefore be suitable as a safe vaccine vector for poultry. Its use as a prototype 1" Present address: Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, U.K. vaccine has been demonstrated by the fact that recombinant FPV expressing the haemagglutinin gene of avian influenza virus affords protection to birds challenged by influenza virus (Taylor et al., 1988 b) . Although FPV does not undergo a productive replication in mammalian species, recombinants expressing rabies virus glycoproteins have been used as vaccines to protect mammals against rabies (Taylor et al., 1988a) . These latter experiments open the way for testing of a wide range of FPV-based vaccines against diseases of mammals and even of humans.
In the poultry field possibly the most important pathogen world-wide is Newcastle disease virus (NDV) (Lancaster & Alexander, 1975) . NDV is a paramyxovirus possessing two major glycoprotein components of the virion envelope, both of which are candidates for inclusion in a recombinant vaccine. These are the fusion (F) protein, which is involved in membrane fusion and virus penetration, and the haemagglutinin-neuraminidase (HN) protein, which allows virus attachment to cells. The F protein is known to play an important role in immunity to the disease (Meulemans et al., 1986) and expression in vaccinia virus recombinants (Meulemans et al., 1988) has shown that this protein alone is sufficient to induce protective immunity to NDV in chickens.
In this paper we show that genes in the terminal inverted repeats of FPV are non-essential for growth in tissue culture. These genes are used as insertion sites for foreign genes in an FPV vector system. To test the usefulness of this vector as a vaccine vector in chickens we have inserted the F gene from the Beaudette C strain of NDV into an FPV recombinant and assessed it for the ability to induce protection against challenge by a virulent strain of NDV.
Methods
Virus and cells. FP9 is a plaque-purified isolate of a tissue cultureadapted strain of FPV HP444 (Mayr & Malicki, 1966) . Px4.1 is a strain derived from the Poxine vaccine strain (Duphar), which we have passaged three times in tissue culture and plaque-purified. Viruses were grown in chick embryo fibroblast (CEF) cells, as described by Binns et al. (1987) .
Construction of plasmid recombination vectors. Plasmid pB3ME (Fig.  1 ) is a clone of the terminal BamHI fragment of the FP9 strain of FPV (Campbell et al., 1989) , which has had the tandem repeats removed by digestion with SstI and religation. A plasmid pEFL16 was constructed by inserting the PvulI fragment from pUCI9 into the SpeI site of pB3ME. The fragment from pUC19 confers on pB3ME a blue/white marker system for detection of plasmids with inserts on plates containing Xgal and has a unique SmaI site for insertion of promoter/gene cartridges.
A plasmid pEFL2 was created by insertion of a BamHI fragment, containing the lacZ gene under the control of the vaccinia virus p7.5 promoter (from pPG l, a kind gift from Dr Paul Gershon) into the BglII site of pB3ME (Fig. 1) . Equivalent plasmids containing the lacZ gene in the NcoI and SpeI sites were designated pEFL6 and pEFL8.
The complete F gene of the Beaudette C strain of NDV was assembled within pUC18 from three partial clones, described by Chambers et al. (1986) . To do this pUC18 was cut within the multiple cloning site with BamHI and PstI and then simultaneously ligated to a 0.6 kb BamHI-SstI fragment from clone 3.01, a 0-5 kb SstI-AvaI fragment from clone 7.58 and 1.25 kb AvaI-PstI fragment from clone 7.44, to give the plasmid pPE2000F. The final clone was checked by sequencing across all the junctions. The F gene was placed under control of the vaccinia virus p7-5 promoter as follows. The gene was excised from pPE2000F by cutting with BamHI (which cuts 29 bases upstream of the initiating ATG codon at the 5' end of the F gene) and HindlII (which cuts approximately 820 bases downstream from the 3' end of the F gene). After repairing the ends of this fragment, using Klenow polymerase, it was ligated into the SmaI site of the plasmid pGS20, which contains the p7-5 promoter (Mackett et al., 1985) . The p7.5 promoter and the F gene were excised from this plasmid using XbaI and NheI (NheI cuts 360 bases downstream of the F gene), endrepaired with Klenow polymerase and cloned into the unique Sinai site of pEFLI6. The resulting plasmid is called pEFF2 (Fig. 1) .
Production of FPV recombinants. Recombination of the plasmid constructs into FPV was carried out essentially as has been described for vaccinia virus (Mackett et al., 1985) . Briefly, 80~ confluent monolayers of CEFs were infected with 3 p.f.u./cell of virus. Two hours post-infection the recombination plasmid, plus 1 ~tg of FPV DNA, was transfected into the cells using the calcium phosphate method. The cells were incubated for 4 to 5 days and then frozen and thawed to release the virus. Virus from the recombinations was plated out on 10 cm 2 Petri dishes at a concentration of virus producing about 1000 plaques per dish. For the lacZ construct the plaques were overlayed with agarose containing the colorigenic substrate Xgal. Recombinant plaques were identified by their blue colour, picked into 10 mM-Tris-HC1 pH 9.0, frozen and thawed three times to release the virus and plaque-purified three times. For the F gene construct viral plaques were lifted onto nitrocellulose (Villareal & Berg, 1977) and probed with a radiolabelled probe specific for the F gene. Recombinant virus containing the F gene sequences was then isolated from the agarose overlay by removing a plug of agarose using a Pasteur pipette. This plug was resuspended in 10 mM-Tris-HC1 pH 9.0, frozen and thawed three times and replaqued. Recombinant virus was again identified by probing and this process was repeated three times until a plaque-purified virus was achieved.
Analysis of a recombinant virus. DNA was extracted from purified virions of the recombinant virus and of the parent virus, as described by Binns et aL (1987) . Restriction enzymes were used according to the manufacturers' recommendations, restricted fragments were analysed on 0.8 % agarose gels and transferred to nitrocellulose by the method of Southern (1975) .
In vivo experiments. FPV was inoculated intravenously (in 0-5 ml of 199 medium) or by the wing-web route (in 50 ~tl of 199 medium) into specified pathogen-free Rhode Island Red chickens. Challenge virus (NDV strain Herts 33) was grown and titrated in embryonated eggs and diluted to a concentration of 105 ELDs0 per 0.5 ml of Eagle's MEM tissue culture medium. Chickens were challenged intramuscularly with 105 ELDso of this virus. All experiments with NDV were carried out under containment conditions as recommended by the Ministry of Agriculture, Fisheries and Food.
SDS-PAGE and Western blotting.
Purified NDV (strain Beaudette C) virions, NDV-infected or FPV-infected cells were boiled for 2 min in SDS-PAGE sample buffer (Laemmli, 1970) containing 1% (w/v) SDS and no reducing agent and electrophoresed in a 10% polyacrylamide gel. Western blotting and detection of bound antibody were as previously described (Samson, 1986) , except that peroxidase-conjugated rabbit anti-chicken antibody was used to detect chicken antibodies. Monoclonal antibody U45 was a gift from Dr D. Alexander and monoclonal antibody 14 was a gift from Dr P. H. Russell.
Haemagglutination inhibition (HI) and ELISA assays. The HI tests were carried out essentially as described by Allan & Gough (1974) using the La Sota strain of NDV as an antigen. The ELISA was carried out in four steps, as follows. At each stage the reagent was incubated for 30 min at 37 °C, unless otherwise stated, with three washes in phosphate-buffered saline (PBS) containing 0.1% NP40 between each step. Firstly, the antigen (NDV strain La Sota, grown in eggs, concentrated 10-fold by methanol precipitation and used at a dilution of 1/10000 in PBS) was adsorbed on to the ELISA plates overnight at 4 °C. Secondly, serial dilutions of chicken sera in 3% bovine serum albumin and 0-5 M-NaCI containing 0.1% NP40 (BNN) were added. Thirdly, specifically bound antibody was detected with rabbit antichicken IgG-alkaline phosphatase conjugate (1/5000 in BNN). Finally the substrate p-nitrophenyl phosphate (1 mg/ml in diethanolamine buffer pH 9.8) was added and the reaction stopped by addition of 3 MNaOH. The A405 was then measured.
Results

Non-essential regions
Sequencing of the terminal BamHI fragment of the FP9 strain of FPV (Campbell et al., 1989) has shown that it contains three open reading frames (ORFs). In order to test whether these are non-essential for growth in tissue culture and are suitable sites for insertion of foreign genes, we have used the lacZ gene of Escherichia coli.
Insertion of N D V F gene into F P V 623
I-
Tandem repeats 6 6.3kb This gene, under the control of an early/late promoter of vaccinia virus, the p7.5 promoter, was inserted into a unique site within each of the three ORFs (Fig. I) . By the process of homologous recombination the interrupted ORFs were introduced into the FPV genome. In each case a stable recombinant virus was isolated, showing that each of the sites was in a non-essential region. DNA from the recombinant viruses was analysed by restriction show the same digests transferred to nitrocellulose and probed with a lacZ-specific probe.
enzyme digestion and Southern blot analysis. Fig. 2 shows a BarnHI digest of fpEFL2, a virus with the insert in the BgllI site. In the recombinant the terminal fragments (a double band at 6.3 kb) have disappeared and have been replaced by a double band at 9-9 kb. This is the size that would be expected if the p7.5 plus lacZ sequences had been inserted into the terminal fragment. The presence of the lacZ sequences is confirmed by probing with a radiolabelled probe specific for lacZ (lanes 3 and 4). These data show that the lacZ gene has been inserted into both ends of the virus and is therefore present in two copies.
Insertion o f F gene into recombinants
The plasmid pEFF2 containing the NDV F gene under the control of the p7.5 promoter inserted into the SpeI site of pB3ME ( Fig. 1 ) was allowed to recombine into FPV. The strain used in this case was a plaque-purified isolate (Px4.1) of a licensed vaccine strain, the Poxine strain, obtained from Duphar. Although the Px4.1 and FP9 strains have different restriction profiles, hybridization data show that it does possess the terminal sequences present in FP9 (data not shown) and it was expected that the plasmids used for recombination into FP9 would be usable for recombination into Px4.1. After recombination the virus was plated out and plaques were probed with an F gene-specific probe. Approximately 0-1 ~ of the plaques were found to contain F sequences and these were picked and subjected to several further rounds of purification. One recombinant virus (fpEFF2) was chosen and its D N A analysed. The data show that the F gene plus promoter has been inserted into both ends of the virus, as was the case for the lacZ gene in the FP9 strain (data not shown).
Analysis of expression of genes in vitro
The lacZ recombinants were known to be expressing fl-galactosidase, as they were isolated on the basis of detecting blue plaques under Xgal agar. To determine whether a correct size of protein was produced Western blotting experiments were carried out. CEF monolayers, infected with the recombinant viruses and the parent strains, were lysed as described in Methods and the proteins separated by P A G E and transferred to nitrocellulose (Samson, 1986) . The proteins were probed with mouse anti-fl-galactosidase antibody and a band of 116K was revealed, the correct size for fl-galactosidase (see Fig. 3 ). The NDV F recombinant was treated in the same way, with the appropriate antisera. For the Western blots a monoclonal antibody (U45) was used, which is known to bind strongly to F protein on Western blots of nonreducing gels. No recombinant-produced F protein was detected, although the monoclonal antibody reacted with F protein from NDV-infected CEFs, nor could F protein be detected by immunofluorescence or immunoprecipiration tests (data not shown).
Analysis of protection of chickens by the recombinant
Two experiments are reported here. In the first (experiment A) we aimed to achieve maximum protection with two inoculations of the recombinant virus at a high dose and in the second (experiment B) we investigated the levels of protection that could be achieved with a single Wing-web 0/6 0/6 0/6 Px4.1 (parent)
Wing-web 4/6 6/6 Uninoculated 9/13 13/13 inoculation at various doses more comparable to those recommended for use with the Poxine vaccine (1028). The vaccination regime for experiment A was as follows. The chickens were inoculated at 14 days of age with 106 p.f.u./chicken of either the r e c o m b i n a n t or the Px4.1 parent F P V strain. A booster inoculation was given at 27 days and the chickens were challenged at 42 days with 105 ELDso of a virulent strain of N D V . The results are shown in Table 1 . In the control groups inoculated with F P V alone, or uninoculated, all the chickens died within 4 days of challenge. Chickens inoculated with the N D V F r e c o m b i n a n t were 1 0 0~ protected against challenge. Inoculation via both the intravenous and wing-web routes gave total protection, all r e c o m b i n a n t -v a c c i n a t e d chickens still being alive 21 days after challenge. In experiment B chickens were inoculated at 14 days of age with three different doses of the r e c o m b i n a n t or of the F P V control, via the wing-web, the normal route of administration of F P V vaccines. No booster was given and the chickens were challenged, as previously, at 42 days. The results are shown in Table 2 . All the control chickens died within 4 days of challenge. In contrast only one of the 42 r e c o m b i n a n t -v a c c i n a t e d chickens had died within 5 days. There was a total of six further deaths in the r e c o m b i n a n t -v a c c i n a t e d chickens, on days 6, 8 and 11. The final levels of protection in the three groups given doses of 5 x 104, 5 x 103 and 5 × 102 were 86, 93 and 71~o, respectively. The levels of protection do not a p p e a r to be related to the dose of the recombinant.
Antibody production by chickens given the recombinant F P V
Chickens from experiment A were bled i m m e d i a t e l y before challenge and the survivors were bled at the end of the experiment (21 days after challenge). In e x p e r i m e n t B chickens were bled at l, 2, 3 and 4 weeks postinoculation, the last bleed being i m m e d i a t e l y before challenge. Surviving chickens were also bled 21 days after challenge. Pre-challenge sera were tested for antibodies to the F protein by Western blots. Sera were also tested for a n t i -N D V a n t i b o d y by E L I S A and HI. Fig. 4 and 5 show the results of probing W e s t e r n blots of 
S D S -P A G E -s e p a r a t e d proteins from purified N D V
virions with sera from chickens inoculated with the F P V / F r e c o m b i n a n t and from control chickens in the two experiments. Sera from chickens inoculated with the N D V F / F P V r e c o m b i n a n t contained a n t i b o d y that bound to the F protein, as can be seen clearly in Fig. 4 , lane 5. The U45 anti-F monoclonal a n t i b o d y also bound to F, as expected (Fig. 4, lane 8) . Neither sera from chickens inoculated with F P V alone nor sera from noninoculated chickens bound significantly to the F protein.
Sera from chickens vaccinated with only a single dose of the F P V / F recombinant (experiment B, Fig. 5 ) had much lower levels of antibody to the F protein. The different levels of antibody can be seen in Fig. 5 by comparing lanes 6 to 9 (single inoculation) to lane 12 (two inoculations).
The lanes in which the goat anti-chicken, but not the rabbit anti-mouse conjugate, was used show strong binding at the top of the gel. A variety of commercial anti-chicken conjugates gave this binding, which is still seen in the absence of chicken serum or calf serum (not shown). Table 3 shows levels of antibody to N D V pre-and post-challenge with N D V . In experiment B a single inoculation with the N D V F / F P V recombinant did not induce detectable levels of antibody, as measured by H I or by ELISA. After challenge with the virulent N D V Herts 33 strain the titres to N D V rose dramatically. In experiment A the two inoculations of the recombinant did induce detectable levels of antibody, as measured by ELISA, although the H I titres were barely above background level. After challenge these titres did not rise to any great extent.
Discussion
Two groups have reported the successful insertion of foreign genes into F P V and testing of the recombinants in chickens. Boyle & Coupar (1988) inserted the gene for the haemagglutinin (HA) protein from human influenza virus into the FPV thymidine kinase gene and demonstrated H I antibodies in chickens. Taylor et al. (1988b) have reported the introduction of the avian influenza H A into an unspecified locus in FPV and demonstrated protective immunity in chickens. We report here new non-essential genes in the terminal inverted repeats of the virus that can be used as insertion sites. The E. coli fl-galactosidase gene has been inserted and expressed in a site in each of the three open reading frames O R F 1, 2 and 3. Different insertion sites are likely to have different characteristics. One characteristic of these sites is that genes inserted into them are present in two copies, which is likely to mean an increase in the amount of the expressed product produced. Such an increased level of expression could be a useful adjunct to increased levels produced by using stronger promoters. The effect of insertion of genes at the SpeI site in O R F 3 has been ELISA: 6000 * The titres shown are mean titres for the group of birds receiving the highest recombinant dose and are expressed as reciprocals of the dilutions. tested and does not seem to attenuate the virus in vivo (data not shown). Sites that attenuate, and those which do not, will be useful in the construction of vaccines, the latter in cases where it is wished to insert a gene into a virus or recombinant virus already having the desired level of attenuation.
The usefulness of vectors containing genes inserted into the terminal regions has been demonstrated in this paper by the use of the fusion protein gene from Newcastle disease virus. Two inoculations with 106 p.f.u./bird of the FPV/F recombinant fpEFF2 gave 100 ~ protection against challenge with 105 ELDs0 of the virulent Herts 33 strain of NDV. Good protection, although not 100K, was demonstrated by the use of a single dose of the recombinant. Although it is possible that higher levels of protection could have been achieved with a single inoculation of 106 p.f.u./bird, the results of the second experiment (Table 2) suggest that the protection is not very dose-dependent: This, would be consistent with the fact that the Poxine FPV vaccine strain is not a highly attenuated strain and probably replicates to the same level in the chicken regardless of the initial dose. Experiments are currently in progress to determine the optimum vaccination regime, using the Px4.1 and other strains of FPV.
The fact that sera from birds inoculated with the FPV/F recombinant contains antibodies to F protein clearly demonstrates that expression of the F protein in the recombinant has occurred. The reason why expression of F has not been demonstrated in vitro is not clear. Expression of a functional /?-galactosidase protein at readily detectable levels can be shown from FPV recombinants with the lacZ gene cloned at the same site and with the same promoter. It is possible that for some reason only very low levels of the F protein accumulate in infected cells and that these levels are too low to be detected by the methods used here. The corollary of this would be that only low levels of the F protein are needed for protection. Another possibility is that an unstable form of the F protein is produced. An unstable, or processed form of the protein might still induce a good protective immunity. Indeed, Townsend et al. (1988) have reported that deliberate engineering of instability of a protein expressed in vaccinia virus was found to increase the cell-mediated immune response to that protein.
It is interesting to note that the good levels of protection demonstrated in these experiments are achieved despite the fairly low levels of antibody induced by the recombinants (Table 3 ). In the case of a single inoculation the HI and ELISA tests failed to detect antibody levels above background, although specific antibodies to the F protein were demonstrated by Western blotting. It might be expected that HI antibodies would be low, since antibodies to the F protein could only inhibit haemagglutination indirectly by binding to the F protein on the virus and sterically blocking adjacent HN molecules. However, the antibody levels as measured by ELISA are also low. In this case the explanation for the low or undetectable levels of antibody to NDV may be due to high backgrounds masking low antibody levels, caused by the effect of the non-specific binding that can be seen at the top of the gels in Fig. 4 and 5. When two inoculations were used the antibody levels were slightly higher. Both antibodymediated (Meulemans et al., 1986) and cell-mediated immunity (Timms & Alexander, 1977) are known to play a role in protection against NDV and, bearing in mind the fairly low levels of antibody detected in the present experiments, it may well be that the protection observed has a substantial cell-mediated component. After challenge with NDV the anti-NDV titres rise dramatically in experiment B, but in experiment A, where the protection is 100~o, the titres hardly increase at all, suggesting that the replication of NDV has been largely prevented.
The demonstration that recombinants based on this FPV vector system can be successfully used to protect chickens against challenge opens the way for the use of such a recombinant vaccine against NDV. Recombinant vaccines using the F gene could have several advantages over conventional vaccines based on attenuated or killed NDV. For example, vaccination with a recombinant FPV expressing the F gene and not the HN gene wouJd allow easy differentiation between antibodies induced by the vaccine and those induced by a natural infection with NDV. Other potential advantages include lack of possible reversion to virulence and lack of undesirable side effects following administration. In addition a recombinant FPV could be used as a multivalent vaccine, expressing genes that have been cloned from other poultry pathogens such as infectious bronchitis virus ), Marek's disease virus (Buckmaster et al., 1988) , infectious bursal disease virus (Hudson et al., 1986) and infectious laryngotracheitis virus (Griffin, 1989) .
